Adaptive Biotechnologies : Q1 2025 Earnings Presentation

Published: 2025-05-01 17:04:57 ET ADPT

Published on 05/01/2025 at 17:04

First Quarter 2025

Earnings Conference Call

MRD revenue $43.7M; +34% Y/Y

Excluding milestones +39% Y/Y

clonoSEQ expanded coverage for MCL recurrence monitoring

Advancing lead autoimmune program

Total operating expenses -9% Y/Y

GM1 68% ; sequencing GM2 62% (+17 ppts Y/Y)

Strong cash3 position: ~$233M in cash3

Q1'25 cash3 burn: ~$23M; (-38% vs Q1'24)

FY 2025 guidance update: increasing MRD revenue range; decreasing OPEX and annual cash burn ranges

1 GM = gross margin

2 Sequencing GM refers to gross margin excluding MRD regulatory milestones and GNE amortization

3 3 Cash, cash equivalents and marketable securities as of 3/31/2025

Clinical testing: volume growth and positive metric trends continue

Clinical testing revenue increased 55% in Q1 2025 Y/Y

44%

of MRD tests in blood in Q1'25

12%

Q1'25 contribution from NHL (DLBCL, MCL)

3,436

Ordering HCPs in Q1'25 (+31% Y/Y)

27

EPIC/EMR integrated accounts

6

Key payer contracts renegotiated / closed

clonoSEQ test volumes

10%

7%

9%

6%

22,368

19,105

17,854

15,095

16,361

20,302

9%

Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25

clonoSEQ US volume

5 © Copyright Adaptive Biotechnologies 2024. Confidential.

Disclaimer

Adaptive Biotechnologies Corporation published this content on May 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 01, 2025 at 21:02 UTC.